Search Results - "Curd, John G"

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer by SUN, Jessica D, QIAN LIU, HART, Charles P, JINGLI WANG, AHLUWALIA, Dharmendra, FERRARO, Damien, YAN WANG, DUAN, Jian-Xin, STEVE AMMONS, W, CURD, John G, MATTEUCCI, Mark D

“…Tumor hypoxia underlies treatment failure and yields a more aggressive, invasive, and metastatic cancer phenotype. TH-302 is a 2-nitroimidazole triggered…”
Get full text

Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer by Sun, Jessica D, Liu, Qian, Wang, Jingli, Ahluwalia, Dharmendra, Ferraro, Damien, Wang, Yan, Duan, Jian-Xin, Ammons, W Steve, Curd, John G, Matteucci, Mark D, Hart, Charles P

Get full text

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules by Liu, Qian, Sun, Jessica D., Wang, Jingli, Ahluwalia, Dharmendra, Baker, Amanda F., Cranmer, Lee D., Ferraro, Damien, Wang, Yan, Duan, Jian-Xin, Ammons, W. Steve, Curd, John G., Matteucci, Mark D., Hart, Charles P.

“…Purpose Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a…”
Get full text

High dose calcitriol may reduce thrombosis in cancer patients by Beer, Tomasz M., Venner, Peter M., Ryan, Christopher W., Petrylak, Daniel P., Chatta, Gurkamal, Dean Ruether, J., Chi, Kim N., Curd, John G., DeLoughery, Thomas G.

“…Summary The incidence of venous and arterial thrombosis in a placebo‐controlled randomised trial of DN‐101 (high dose calcitriol) with docetaxel versus…”
Get full text

C-reactive Protein as a Prognostic Marker for Men With Androgen-independent Prostate Cancer : Results From the ASCENT Trial by BEER, Tomasz M, LALANI, Alshad S, CHI, Kim N, LEE, Stella, MORI, Motomi, EILERS, Kristine M, CURD, John G, HENNER, W. David, RYAN, Christopher W, VENNER, Peter, RUETHER, J. Dean

“…Studies of cancer risk and molecular carcinogenesis suggest a role for inflammation in cancer development and progression. The authors sought to determine…”
Get full text

C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer by Beer, Tomasz M., Lalani, Alshad S., Lee, Stella, Mori, Motomi, Eilers, Kristine M., Curd, John G., Henner, W. David, Ryan, Christopher W., Venner, Peter, Ruether, J. Dean, Chi, Kim N.

“…BACKGROUND. Studies of cancer risk and molecular carcinogenesis suggest a role for inflammation in cancer development and progression. The authors sought to…”
Get full text

Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema by Schapira, M, Silver, L D, Scott, C F, Schmaier, A H, Prograis, Jr, L J, Curd, J G, Colman, R W

“…Patients with hereditary angioedema lack C-1 inhibitor, a plasma alpha 2-glycoprotein that inhibits both the proteolytic action of C1, the activated first…”
Get more information

Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease by Ellison, 3rd, R T, Kohler, P F, Curd, J G, Judson, F N, Reller, L B

“…We evaluated the complement system in 20 patients presenting with a first episode of meningococcal meningitis, meningococcemia, or meningococcal pericarditis…”
Get more information

Abstract 5388: Sequence- and regimen-dependent combination therapy with the hypoxia-activated Prodrug TH-302 and Doxorubicin in a preclinical sarcoma xenograft model by Sun, Jessica D., Liu, Qian, Ahluwalia, Dharmendra, Curd, John G., Hart, Charles P.

“…Tumor hypoxia is associated with resistance to standard chemotherapy, cancer relapse, and poor prognosis. TH-302 is a 2-nitroimidazole triggered…”
Get full text

Abstract A42: Antiangiogenic-induced increase in tumor hypoxia in RCC and NSCLC human tumor xenografts and its selective targeting by the hypoxia-activated prodrug TH-302: A model for clinical exploration? by Hart, Charles P., Ahluwalia, Dharmendra, Liu, Qian, Meng, Fanying, Bhupathi, Deepthi, Curd, John G., Matteucci, Mark D.

“…Several published studies have demonstrated an increase in tumor hypoxia after administration of anti-angiogenesis agents that target VEGF signaling (e.g.,…”
Get full text

Abstract 535: Hypoxia-dependent in vivo activity of the hypoxia-activated prodrug (HAP) TH-302 by Sun, Jessica D., Liu, Qian, Ahluwalia, Dharmendra, Wang, Yan, Meng, Fanying, Bhupathi, Deepthi, Curd, John G., Matteucci, Mark D., Hart, Charles P.

“…Hypoxia is a defining feature of solid tumors, associated with treatment failure, poor prognosis, cancer relapse and increased metastatic potential…”
Get full text

Abstract 5054: Hypoxia-activated prodrug TH-302 enhances antitumor activity of antiangiogenics in preclinical models by Sun, Jessica D., Ahluwalia, Dharmendra, Liu, Qian, Wang, Yan, Meng, Fanying, Bhupathi, Deepthi, Curd, John G., Matteucci, Mark D., Hart, Charles P.

“…Antiangiogenics have revolutionized cancer therapy. Angiogenesis is a critical step in the establishment, growth, and metastasis of solid tumors. However,…”
Get full text

Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models by Sun, Jessica D., Liu, Qian, Ahluwalia, Dharmendra, Wang, Yan, Meng, Fanying, Bhupathi, Deepthi, Curd, John G., Matteucci, Mark D., Hart, Charles P.

“…TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug (HAP). In hypoxic cells the DNA cross-linker bromo-isophosphoramide mustard (Br-IPM) is…”
Get full text

Abstract B185: Bench to bedside experience with TH-302: A tumor-selective hypoxia-activated prodrug as a promising treatment for prostate cancer by Hart, Charles P., Armstrong, Andrew J., Chiorean, Elena G., Sun, Jessica D., Langmuir, Virginia K., Meng, Fanying, Eng, Clarence, Kroll, Stewart, Matteucci, Mark D., Curd, John G.

“…Hypoxia is a defining feature of solid tumors, including prostate cancer. Metastases also exhibit subregional hypoxia and micrometastases may be severely…”
Get full text

Different patterns of C3 and C4 activation in the varied types of juvenile arthritis by MILLER, J. J, OLDS, L. C, SILVERMAN, E. D, MILGROM, H, CURD, J. G

“…Quantitative assays for C3 and C4 activation were carried out simultaneously on blood from children with varied types of juvenile arthritis. Factor…”
Get full text

Sjögren's syndrome. Proposed criteria for classification by Fox, R I, Robinson, C A, Curd, J G, Kozin, F, Howell, F V

“…The term "Sjögren's syndrome" (SS) is frequently used to describe the occurrence of keratoconjunctivis sicca and xerostomia in association with an autoimmune…”
Get more information

A Novel N-Oxide Drug, AQ4N, Has In Vitro Activity in Lymphoma and Leukemia Cell Lines and Selectively Targets Lymphocytes and Lymphatic Tissues in Vivo by Cleland, Jeffrey L., Wong, Alvin, Alters, Susan E., Harris, Peter A., Dunk, Chris R., Curd, John G., Capizzi, Robert L., Henner, William D.

“…An ideal treatment for lymphoma and leukemia is the use of highly selective compounds to eliminate diseased cells with minimal systemic toxicity to normal…”
Get full text

Probability analysis of the interaction of antibodies with multideterminant antigens in radioimmunoassay: application to the amino terminus of the β chain of hemoglobin S by Berzofsky, Jay A, Curd, John G, Schechter, Alan N

“…A simple theory, based on probability, is developed for the analysis of the interaction of multideterminant antigens with multispecific antisera in…”
Get full text

Leukocyte Complement: Assembly of the Membrane Attack Complex of Complement by Human Peripheral Blood Leukocytes in the Presence and Absence of Serum by Sundsmo, John S, Curd, John G, Kolb, William P, Muller-Eberhard, Hans J

“…The specific neoantigenic determinants (neoAg) that are indicative of the assembled C5b-9 C complex are generated on the surface of peripheral blood leukocytes…”
Get full text

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo : a novel approach to immunosuppressive therapy by CARRERA, C. J, TERAI, C, LOTZ, M, CURD, J. G, PIRO, L. D, BEUTLER, E, CARSON, D. A

“…Lymphoid cells were thought to be uniquely susceptible to excess 2'-deoxyadenosine (dAdo), when exposed to inhibitors of adenosine deaminase (ADA). However, we…”
Get full text